Physician profile
Anna Boyman
NPI 1154369361
$2,682.49
in general payments reported to CMS, 2019-2025
13 companies · $103 in 2025
The $103 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $80.92 · 2020: $32.81 · 2021: $166 · 2022: $335 · 2023: $493 · 2024: $1,471 · 2025: $103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,067.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,067.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $720.00 | 2022-2025 | Durysta |
| Alcon Vision LLC | $321.80 | 2022-2024 | Simbrinza, Centurion |
| Sun Pharmaceutical Industries INC. | $315.94 | 2020-2023 | Cequa, Xelpros |
| Johnson & Johnson Surgical Vision, INC. | $311.53 | 2019-2024 | Tecnis Iol |
| Harrow Eye, LLC | $283.42 | 2024 | Vevye |
| Rxsight INC | $261.10 | 2024 | Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd), Light Adjustable Lens (Lal) |
| Glaukos Corporation | $166.78 | 2024 | Idose |
| Bausch & Lomb Americas INC. | $113.96 | 2022-2023 | Vyzulta, Prolensa |
| Biotissue Holdings INC. | $62.66 | 2021 | |
| Aerie Pharmaceuticals, INC. | $47.69 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $29.15 | 2025 | Xdemvy |
| Dompe US, INC. | $25.65 | 2023 | Oxervate |
| Astellas Pharma US INC | $22.81 | 2024 | Izervay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Boyman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.